Melissa Agsalda-Garcia to Anti-HIV Agents
This is a "connection" page, showing publications Melissa Agsalda-Garcia has written about Anti-HIV Agents.
Connection Strength
0.251
-
Kettlewell J, Barney M, Oda R, Agsalda-Garcia M, Siriwardhana C, Shiramizu B. Pre-exposure Prophylaxis Therapy and the Blood-Brain Barrier: Is PrEP Neuroprotective? J Neuroimmune Pharmacol. 2020 03; 15(1):10-12.
Score: 0.130
-
Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neurovirol. 2014 Dec; 20(6):571-82.
Score: 0.091
-
Premeaux TA, D'Antoni ML, Abdel-Mohsen M, Pillai SK, Kallianpur KJ, Nakamoto BK, Agsalda-Garcia M, Shiramizu B, Shikuma CM, Gissl?n M, Price RW, Valcour V, Ndhlovu LC. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol. 2019 04; 25(2):150-161.
Score: 0.030